JRE 1756 · June 27, 2024

John Abramson

healthbusinesssciencepolitics

Who is John Abramson?

John Abramson, MD, is a Harvard Medical School Lecturer, national drug litigation expert, and author. His new book, "Sickening: How Big Pharma Broke American Health Care and How We Can Repair It," will be available on February 8.

Topics and Timestamps

01John Abramson breaks down how Big Pharma manipulates drug research and marketing to maximize profits over patient health
02The pharmaceutical industry strategically designs clinical trials to make drugs look better than they actually are
03Drug companies hide negative trial data and selectively publish only results that support their products
04Marketing directly to doctors through pharma reps has become more influential than actual scientific evidence
05The FDA approval process has fundamental flaws that allow dangerous drugs to reach the market
06Abramson explains how his new book details systemic corruption in American healthcare and what needs to change
▶Abramson introduces his new book and explains the core thesis about pharmaceutical corruption0:00:00
▶Discussion of how drug companies design clinical trials to produce desired results0:10:30
▶Explanation of the FDA approval process flaws and industry influence on regulators0:25:15
▶Abramson details how pharmaceutical sales reps influence doctor prescribing patterns0:40:45
▶Discussion of solutions and what meaningful reform would require in American healthcare0:55:00

The Show

Joe Rogan sits down with Dr. John Abramson, a Harvard Medical School lecturer and drug litigation expert, to discuss the pervasive corruption in the pharmaceutical industry. Abramson, who has spent years investigating how Big Pharma operates, brings a wealth of insider knowledge about how the system is rigged against patients and in favor of corporate profits.

The conversation centers on Abramson's new book, 'Sickening: How Big Pharma Broke American Health Care and How We Can Repair It,' which details the systematic ways pharmaceutical companies manipulate clinical trials, hide unfavorable data, and market drugs to doctors through direct influence rather than scientific merit. Abramson explains that the industry doesn't necessarily set out to harm people, but the financial incentive structure creates a system where profits inevitably take precedence over patient safety.

One of the most damning aspects Abramson discusses is how drug companies design their clinical trials strategically. Rather than running head-to-head comparisons against existing treatments or placebos that would show true efficacy, they often run trials against inferior comparisons or use dosing schedules that make their drugs appear more effective than reality. He gives multiple examples of blockbuster drugs that showed minimal actual benefit for patients while generating billions in revenue.

The FDA approval process comes under significant scrutiny during the episode. Abramson details how the regulatory framework has been weakened over decades, particularly since the Prescription Drug User Fee Act, which ironically allows the pharmaceutical companies being regulated to fund the regulators. This creates an inherent conflict of interest that pushes the FDA toward approving drugs rather than rigorously protecting the public.

Abramson also discusses how pharmaceutical marketing has become disconnected from science. Drug companies employ thousands of sales representatives who visit doctors with the latest marketing materials, and these personal relationships often matter more than clinical evidence when doctors make prescribing decisions. The industry spends more money on marketing than on research and development, a fact that speaks volumes about where their priorities lie.

Throughout the conversation, Joe and Abramson explore the real-world consequences of this corruption. Patients are prescribed medications they don't need, at doses higher than necessary, often for conditions the drugs barely treat. Meanwhile, safer and more effective alternatives sometimes exist but aren't profitable enough for companies to promote aggressively.

Abramson's approach isn't purely condemning the system without offering solutions. He discusses what meaningful reform would require, including restructuring financial incentives, increasing transparency in clinical data, and fundamentally changing how the FDA operates. The conversation reveals why these reforms haven't happened despite decades of evidence that the system is broken: the pharmaceutical industry has enormous political power and financial resources to maintain the status quo.

Best Quotes

“The pharmaceutical industry isn't necessarily evil, but the financial incentive structure creates a system where profits inevitably come before patient safety.”

— John Abramson